Patient Information Resources


Orthogate
1089 Spadina Road
Toronto, AL M5N 2M7
Ph: 416-483-2654
Fax: 416-483-2654
christian@orthogate.com






Ankle
Child Orthopedics
Elbow
Foot
General
Hand
Hip
Knee
Shoulder
Spine - Cervical
Spine - Lumbar
Spine - Thoracic
Wrist

View Web RX

« Back

Bisphosphonates Preserve Hip in Children with Osteonecrosis

Posted on: 08/30/2007
Femoral head osteonecrosis is the death of bone at the top of the femur (thighbone). It can occur after trauma in children and has a poor outcome. In this study, doctors at the Children's Hospital at Westmead in Australia try a new treatment to prevent this from happening.

This is the first study in children to use bisphosphonates to prevent osteonecrosis. Bisphosphonates are a class of anti-resorption drugs used for bone cancer patients or for osteoporosis in older adults. Anti-resorptive means they keep the bone from breaking down. They also can improve bone density. So far, only animal and human adult studies have been done.

Children who had surgery for slipped capital femoral ephiphysis (SCFE), femoral neck fractures, or hip dislocation were included. Bone scans were done to detect osteonecrosis. Bisphosphonate therapy was started in any child who had a positive bone scan.

The drug was given intravenously (IV). This method of delivery helps improve absorption. More of the drug is available for use in the body compared with taking an oral dose in pill form. IV administration also made sure the child got the medication.

The children were monitored every three months for at least two years. X-rays and an exam were done to watch for complications. There were no major adverse effects of the drug. No negative effects on growth were seen in the children. The use of bisphosphonates was successful in all children included in the study.

The authors saw signs of bone resorption for up to 18 months after the initial injury. They suggested a higher dose of drug may have been needed. Right now the best dose and duration of bisphosphonate to use is unknown. Further study is needed to find the right balance to protect bone without increasing the risk of adverse side effects.

References:
Manoj Ramachandran, FRCS (Tr&Orth), et al. Intravenous Bisphosphonate Therapy for Traumatic Osteonecrosis of the Femoral Head in Adolescents. In The Journal of Bone and Joint Surgery. 89-A. No. 8. Pp. 1727-1734.

« Back





*Disclaimer:*The information contained herein is compiled from a variety of sources. It may not be complete or timely. It does not cover all diseases, physical conditions, ailments or treatments. The information should NOT be used in place of visit with your healthcare provider, nor should you disregard the advice of your health care provider because of any information you read in this topic.


All content provided by eORTHOPOD® is a registered trademark of Mosaic Medical Group, L.L.C.. Content is the sole property of Mosaic Medical Group, LLC and used herein by permission.